Tango Therapeutics TNGX Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's other income, net (note 6)?
- Tango Therapeutics (TNGX) reported other income, net (note 6) of $1.08M in Q1 2026.
- How has Tango Therapeutics's other income, net (note 6) changed year-over-year?
- Tango Therapeutics's other income, net (note 6) increased by 0.5% year-over-year, from $1.07M to $1.08M.
- What is the long-term trend for Tango Therapeutics's other income, net (note 6)?
- Over 4 years (2021 to 2025), Tango Therapeutics's other income, net (note 6) has grown at a 101.3% compound annual growth rate (CAGR), from -$248K to $4.07M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.